Haefner Burkhard
Department of Inflammatory Disease, Johnson & Johnson Pharmaceutical Research & Development, a Division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, 2340 Beerse, Belgium.
Drug Discov Today. 2003 Jun 15;8(12):536-44. doi: 10.1016/s1359-6446(03)02713-2.
In recent years, marine natural product bioprospecting has yielded a considerable number of drug candidates. Most of these molecules are still in preclinical or early clinical development but some are already on the market, such as cytarabine, or are predicted to be approved soon, such as ET743 (Yondelis). Research into the ecology of marine natural products has shown that many of these compounds function as chemical weapons and have evolved into highly potent inhibitors of physiological processes in the prey, predators or competitors of the marine organisms that use them. Some of the natural products isolated from marine invertebrates have been shown to be, or are suspected to be, of microbial origin and this is now thought to be the case for the majority of such molecules. Marine microorganisms, whose immense genetic and biochemical diversity is only beginning to be appreciated, look likely to become a rich source of novel chemical entities for the discovery of more effective drugs.
近年来,海洋天然产物的生物勘探已产生了相当数量的候选药物。这些分子大多仍处于临床前或早期临床开发阶段,但有些已上市,如阿糖胞苷,或预计很快会获批,如ET743(曲贝替定)。对海洋天然产物生态学的研究表明,这些化合物中有许多起着化学武器的作用,并已演变成对使用它们的海洋生物的猎物、捕食者或竞争者的生理过程的高效抑制剂。从海洋无脊椎动物中分离出的一些天然产物已被证明或被怀疑是微生物来源,现在认为大多数此类分子都是如此。海洋微生物的巨大遗传和生化多样性才刚刚开始被认识,它们似乎有可能成为发现更有效药物的新型化学实体的丰富来源。